Medicine for relieving severe asthma, application and animal model construction method

A technology of animal model and construction method, which is applied in the direction of medical formula, drug combination, and medical preparations containing active ingredients, etc., and can solve problems such as unclear mechanism of action, unclear pathogenesis of severe asthma, and difficult clinical treatment

CN113018439APending Publication Date: 2021-06-25AFFILIATED HOSPITAL OF GUANGDONG MEDICAL UNIV
0 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2021-06-25

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the technical field of severe asthma action mechanisms, and discloses a medicine for relieving severe asthma, application and an animal model construction method, the medicine is an HDAC10 inhibitor, and the action mechanism of HDAC10 for regulating and controlling Th17 / IL-17A expression in severe asthma is clarified by using the construction method; the interaction mode of HDAC10 and STAT3 is defined; it is proved that HDAC10 deacetylated STAT3 regulates and controls the expression of Th17 / IL-17A in severe asthma. it is determined that the HDAC10 inhibitor can relieve severe asthma, and an experimental basis is provided for HDAC10 targeted therapy of severe asthma. it is determined that the HDAC10 inhibitor can relieve severe asthma, and an experimental basis is provided for HDAC10 targeted therapy of severe asthma. Compared with a control group, the intraperitoneal injection of the HDAC10 inhibitor can improve airway inflammation, airway hyperreactivity and airway mucus secretion of a severe asthma mouse model mainly comprising neutrophile granulocytes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The present invention belongs to the technical field of severe asthma, and more particularly to drugs, applications and animal model constructs for alleviating severe asthma. Background technique

[0002] There are currently 300 million asthma patients around the world, and there are about 3 million asthma patients in my country, is one of the highest asthma. Therefore, studying asthma occurring and developing new molecular mechanisms, looking for new asthma treatment is still an urgent task of asthma researchers. Clinical studies have found more than 40% of asthma based on neutral granulocyte inflammation. At the same time, about 10% to 15% severe asthma patients are not sensitive to even large doses of glucocorticoid inhalation, or have a certain degree of resistance [2]. Most of these patients are severe asthma, and their fertile features are different from mild asthma, while similar to slow resistance. The traditional TH2 type immune response cannot exp...

Examples

Embodiment Construction

[0029] In order to make the objectives, technical solutions and advantages of the present invention, the present invention will be further described in detail below with reference to the embodiments. It should be understood that the specific embodiments described herein are merely intended to illustrate the invention and are not intended to limit the invention.

[0030] For the problems of the prior art, the present invention provides a method of alleviating a medicament, application, and animal model construct of severe asthma, and a detailed description of the invention will be described in connection with the accompanying drawings.

[0031] Such as figure 1 As shown, the animal model construction method provided by the present invention includes the following steps:

[0032] S101: Using HDAC10 lymphocyte condition knockout (HDAC10 fl / fl Constructs astatic asthma model in mice. The total number of cells were detected by mice AHR and alveolar lavewater (BALF) was detected by a to...